Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cysteine-rich with EGF-like domain protein 2 (CRELD2)
- Target
- CRELD2
- Molecular classification
- Enzyme (protein disulfide isomerase-like activity), Chaperone, Secreted protein, Other (cysteine-rich, EGF-like domain protein family)
01
Overview
Cysteine-rich with EGF-like domain protein 2 (CRELD2) is a multifunctional glycoprotein primarily localized to the endoplasmic reticulum (ER) and Golgi apparatus, possessing protein disulfide isomerase-like activity via multiple CXXC motifs at its N-terminus, which facilitate thiol-disulfide oxidation, reduction, and isomerization essential for ER protein quality control. CRELD2 is inducible under ER stress and can be secreted, particularly in stress conditions, through a process regulated by its C-terminal (R/H)EDL retention motif, and is thought to be involved in cellular responses associated with unfolded protein response, bone/cartilage biology, and homeostasis of various tissues. Its disease associations include cancers, chronic liver, cardiovascular, and kidney diseases, and it may serve as a general marker for perturbed ER homeostasis. It does not currently have known direct drug interactions or established therapeutic interventions.
- Other names
- CRELD2Protein disulfide isomerase CRELD2UNQ185/PRO211MGC11256Cysteine-rich with EGF-like domains 2
02
Mechanism of action
Not applicable (no approved drugs known to directly act on CRELD2)
03
Biological functions
Protein folding and quality control in the endoplasmic reticulumThiol-disulfide oxidation, reduction, and isomerizationUnfolded protein responseER stress responseModulation of osteogenic differentiation and bone/cartilage metabolismChaperone activity (notably for certain membrane proteins)
04
Disease associations
CancerChronic liver diseaseCardiovascular diseaseKidney diseaseBone and cartilage disordersOther ER stress-related diseases
05
Safety considerations
None specifically reported as of current literature; therapeutic targeting or modulation of CRELD2's activity remains exploratory
06
Biomarkers
Potential marker of ER stressPossible surrogate biomarker for disease states involving unfolded protein response (not clinically established)
Beyond the preview
Go deeper on Cysteine-rich with EGF-like domain protein 2 (CRELD2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cysteine-rich with EGF-like domain protein 2 (CRELD2).